Literature DB >> 10574914

Characteristics for a salt-bridge switch mutation of the alpha(1b) adrenergic receptor. Altered pharmacology and rescue of constitutive activity.

J E Porter1, D M Perez.   

Abstract

Agonist-dependent activation of the alpha(1)-adrenergic receptor is postulated to be initiated by disruption of an interhelical salt-bridge constraint between an aspartic acid (Asp-125) and a lysine residue (Lys-331) in transmembrane domains three and seven, respectively. Single point mutations that disrupt the charges of either of these residues results in constitutive activity. To validate this hypothesis, we used site-directed mutagenesis to switch the position of these amino acids to observe, if possible, regeneration of the salt-bridge reverses that the constitutive activity of the single point mutations. The transiently expressed switch mutant receptor displayed an altered pharmacological profile. The affinity of selective alpha(1b)-adrenergic receptor antagonists for the switch mutant (D125K/K331D) was no different from the wild-type alpha(1b)-adrenergic receptor, suggesting that both receptors are maintaining similar tertiary structures in the cell membrane. However, there was a significant 4-6-fold decrease in the affinity of protonated amine receptor agonists and a 3-6-fold increase in the affinity of carboxylated catechol derivatives for the switch mutant compared with the wild-type alpha(1b)-adrenergic receptor. This pharmacology is consistent with a reversed charge at position 125 in transmembrane domain three. Interestingly, the ability of either a negatively or positively charged agonist to generate soluble inositol phosphates was similar for both types of receptors. Finally, the switch mutant (D125K/K331D) displayed similar basal signaling activity as the wild-type receptor, reversing the constitutive activity of the single point mutations (D125K and K331D). This suggests an ionic constraint has been reformed in the switch mutant analogous to the restraint previously described for the wild-type alpha(1b)-adrenergic receptor. These results strongly establish the disruption of an electrostatic interaction as an initial step in the agonist-dependent activation of alpha(1)-adrenergic receptors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10574914     DOI: 10.1074/jbc.274.49.34535

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Simplified modeling approach suggests structural mechanisms for constitutive activation of the C5a receptor.

Authors:  Gregory V Nikiforovich; Garland R Marshall; Thomas J Baranski
Journal:  Proteins       Date:  2010-11-30

2.  Understanding the effects on constitutive activation and drug binding of a D130N mutation in the β2 adrenergic receptor via molecular dynamics simulation.

Authors:  Yanyan Zhu; Yuan Yuan; Xiuchan Xiao; Liyun Zhang; Yanzhi Guo; Xuemei Pu
Journal:  J Mol Model       Date:  2014-10-25       Impact factor: 1.810

3.  Non-specific binding and general cross-reactivity of Y receptor agonists are correlated and should importantly depend on their acidic sectors.

Authors:  M S Parker; R Sah; A Balasubramaniam; F R Sallee; O Zerbe; S L Parker
Journal:  Peptides       Date:  2010-11-30       Impact factor: 3.750

4.  Computational model of the complex between GR113808 and the 5-HT4 receptor guided by site-directed mutagenesis and the crystal structure of rhodopsin.

Authors:  M L López-Rodríguez; M Murcia; B Benhamú; M Olivella; M Campillo; L Pardo
Journal:  J Comput Aided Mol Des       Date:  2001-11       Impact factor: 3.686

5.  Novel human alpha1a-adrenoceptor single nucleotide polymorphisms alter receptor pharmacology and biological function.

Authors:  Beilei Lei; Daniel P Morris; Michael P Smith; Laura P Svetkey; Mark F Newman; Jerome I Rotter; Thomas A Buchanan; Stephen M Beckstrom-Sternberg; Eric D Green; Debra A Schwinn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-03-10       Impact factor: 3.000

6.  Constitutive activation of the neurotensin receptor 1 by mutation of Phe(358) in Helix seven.

Authors:  Séverine Barroso; Françoise Richard; Delphine Nicolas-Ethève; Patrick Kitabgi; Catherine Labbé-Jullié
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

7.  An intracellular interaction network regulates conformational transitions in the dopamine transporter.

Authors:  Julie Kniazeff; Lei Shi; Claus J Loland; Jonathan A Javitch; Harel Weinstein; Ulrik Gether
Journal:  J Biol Chem       Date:  2008-04-21       Impact factor: 5.157

8.  The functional consequences of mis-sense mutations affecting an intra-molecular salt bridge in arylsulphatase A.

Authors:  Frank Schestag; Afshin Yaghootfam; Matthias Habetha; Peter Poeppel; Frank Dietz; Roger A Klein; Joel Zlotogora; Volkmar Gieselmann
Journal:  Biochem J       Date:  2002-10-15       Impact factor: 3.857

9.  Structural impact of the E113Q counterion mutation on the activation and deactivation pathways of the G protein-coupled receptor rhodopsin.

Authors:  Jörg Standfuss; Ekaterina Zaitseva; Mohana Mahalingam; Reiner Vogel
Journal:  J Mol Biol       Date:  2008-04-30       Impact factor: 5.469

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.